Do you about know the most influential innovative people in the world, TIME 100’s list honors the world’s most influential people of the year 2021, the list contains the mixture of extraordinary innovators, all working to build a better future—from Jensen to Elon all are giving back to society.
Artificial intelligence is changing our reality. The product that empowers PCs to do things that once required human insight and judgment relies to a great extent upon hardware made conceivable by Jensen Huang.
In 2003, in the midst of extraordinary distrust, Huang coordinated his organization Nvidia to adjust chips intended to paint illustrations on PC screens, known as designs handling units or GPUs, to perform other, more broadly useful processing assignments. The subsequent progressions—and incredible chips—established a framework that could oblige a lot greater neural organizations, the projects behind a lot of the present AI. Simultaneously, he has empowered an upset that permits telephones to respond to inquiries for all to hear, ranches to shower weeds yet not crops, specialists to foresee the properties of new medications—with more ponders to come.
Huang’s bet paid off generally as he is among the world’s most actually savvy CEOs. He’s additionally a humane steward of his representatives and a liberal ally of instruction in science and innovation. With still emerging AI innovations making an unquenchable yearning for more calculation, Huang’s group is all around situated to continue to drive mechanical advances for quite a long time to come.
Elon Musk is a South African-born American entrepreneur and businessman who founded X.com in 1999 (which later became PayPal), SpaceX in 2002 and Tesla Motors in 2003. Musk became a multimillionaire in his late 20s when he sold his start-up company, Zip2, to a division of Compaq Computers.
Musk made headlines in May 2012, when SpaceX launched a rocket that would send the first commercial vehicle to the International Space Station. He bolstered his portfolio with the purchase of SolarCity in 2016 and cemented his standing as a leader of industry by taking on an advisory role in the early days of President Donald Trump’s administration.
Katalin Karikó leads the mRNA-based protein replacement program for BioNTech RNA Pharmaceuticals.
She has more than 30 years of experience working with RNA. Prior to joining BioNTech RNA
Pharmaceuticals, Dr. Karikó was on the faculty at the University of Pennsylvania Medical School for 25
years. There she investigated RNA-mediated immune activation and in a groundbreaking research she
discovered that nucleoside modifications suppress immunogenicity of RNA. In 2006, she co-founded and
served as CEO of RNARx. With the support of NIH, her team demonstrated in animals, including
macaques the feasibility of using nucleoside-modified mRNA for protein replacement, thus opening a
new field of therapy. She published more than 60 peer-reviewed papers and reviews many of them
focusing on mRNA technologies. Dr. Karikó is co-inventor on mRNA-related patents, including the one
awarded for RNA containing modified nucleosides.
Barra made history by becoming the first female CEO of GM. She added Chairman of the Board to her title only two years later. She spearheads customer-focused changes and innovative technologies to meet GM customers’ needs.
As Barra leads GM into a future of electric cars, one of the top Mary Barra quotes is her motto: “Zero crashes. Zero emissions. Zero congestion.”
Barra has received several awards and honors, including:
● Featured on the cover of Time’s “100 Most Influential People in the World.”
● Forbes ranked her the 35th Most Powerful Woman in the World in 2013. She rose to the rank of #2 in 2018.
● Ranked #1 on Fortune’s list of Most Powerful Women in 2016 and remained in the spot for 2017.
Barra also emerged as a strong leader in May 2020 as GM moved forward to get employees back to work during the COVID-19 pandemic. MLive reported that Barra sent a back-to-work package, including five face masks and a letter, to each GM employee’s home. Under Mary’s leadership, most GM manufacturing plants restarted production with a single shift on May 18.
Barney S. Graham is an immunologist, virologist and clinical trials physician. He currently serves as the Deputy Director of the Vaccine Research Center at the National Institutes of Health and the Chief of the Viral Pathogenesis Laboratory.
One comment in Dr. Graham’s short biography defines the importance of Dr. Graham’s work. “He is one of the first people called upon when a deadly virus outbreak occurs,” the bio declares. That statement rang true in early January of 2020 when Dr. Graham was called upon to develop a vaccine for COVID-19.
In the early days of the pandemic, Graham built upon his research of virus spike proteins in MERS and respiratory syncytial virus (RSV) to find ways to defeat the novel coronavirus. Leveraging an existing relationship with Moderna, Graham brought his modified spike protein to the biotech startup’s messenger-RNA platform and began developing plans for a vaccine. He delivered his plans on January 13, 2020 (just days after the SARS-Cov-2 sequence was provided by the Chinese), and six weeks later, Moderna began shipping vials of the vaccine for clinical trials. Pfizer also used Graham’s modified spike protein in its vaccine, and Eli Lily utilized Graham’s spike protein in its monoclonal antibody treatment.
Graham has earned the title of “the chief architect of the first authorized COVID vaccines,” and because of the high levels of effectiveness and the speed in which the vaccines were developed, thousands – perhaps millions – of lives will be saved by this University of Kansas School of Medicine alumnus. High praise comes from Dr. Anthony Fauci, Graham’s supervisor at the NIH. Of Graham, Fauci said, “He understands vaccinology better than anyone I know.”
Even before his work with COVID-19, Dr. Graham had been improving lives around the world through vaccine development and research. When faced with fighting the Ebola and Zika viruses, the NIH and World Health Organization immediately sought Dr. Graham’s help. He rose to the challenge and established programs to create and evaluate vaccines for those diseases. His work with RSV, a virus that causes more hospitalizations of children under five than any other virus, is currently in Phase III human trials.
Dr. Graham also has empowered a generation of new investigators by sharing his passion with trainees. He mentors medical students, fellows, doctoral candidates and post-doctoral scholars. He hosts sabbaticals for visiting professors from institutions all over the world so they can work on public health issues.
Before earning his M.D. from the University of Kansas School of Medicine in 1979, Graham graduated valedictorian of Paola (Kansas) High School and magna cum laude from Rice University. He continued his training at Vanderbilt University where he completed his internship, residency, two chief residencies and an infectious diseases fellowship. Not quite done with his education, he also earned his Ph.D. in Microbiology and Immunology in 1991 from Vanderbilt.